Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo Holdings Acquires BBI Group In Deal Worth Over $400M

Executive Summary

To bolster its life sciences and diagnostics portfolios, Novo Holdings has made another major investment to acquire BBI Group.

You may also be interested in...



Venture Life Grabs BBI And Leading BV Brand Balance Activ

UK-based Venture Life has gained a foothold in the growing women's health category with the acquisition of BBI Healthcare and its leading OTC BV treatment Balance Activ.

More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode

Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.

UK Government Points At Oximeters For Contributing To Disparity In COVID-19 Outcomes

Sajid Javid, the UK’s secretary of state for health and social care, wants to collaborate with the US Department of Health and Human Services to investigate biases in monitoring and diagnostic devices.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144070

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel